Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (451-460 of 557) with videos related to

Pageof 56
Sort By:
Hypertension (Dallas, Tex. : 1979)|July 18, 2018
Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial InfarctionDavid Carrick, Caroline Haig, Annette M Maznyczka, et al.
European Journal of Heart Failure|July 5, 2019
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fractionLi Shen, Rasmus Rørth, Deborah Cosmi, et al.
JACC. Cardiovascular Imaging|July 23, 2018
Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological InsightsCaroline Haig, David Carrick, Jaclyn Carberry, et al.
European Journal of Heart Failure|March 9, 2017
Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCMKaren Sliwa, Alexandre Mebazaa, Denise Hilfiker-Kleiner, et al.
ESC Heart Failure|May 8, 2024
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and designJaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
European Journal of Heart Failure|June 19, 2024
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial DiseasesPetar M Seferović, Walter J Paulus, Giuseppe Rosano, et al.
European Journal of Heart Failure|September 15, 2023
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESCAntoni Bayes-Genis, Kieran F Docherty, Mark C Petrie, et al.
Heart (British Cardiac Society)|February 12, 2025
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trialShirley Sze, Iain Squire, Paul R Kalra, et al.
JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Pageof 56

Showing results (451-460 of 557) with videos related to

Sort By:
Pageof 56
Hypertension (Dallas, Tex. : 1979)|July 18, 2018
Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial InfarctionDavid Carrick, Caroline Haig, Annette M Maznyczka, et al.
European Journal of Heart Failure|July 5, 2019
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fractionLi Shen, Rasmus Rørth, Deborah Cosmi, et al.
JACC. Cardiovascular Imaging|July 23, 2018
Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological InsightsCaroline Haig, David Carrick, Jaclyn Carberry, et al.
European Journal of Heart Failure|March 9, 2017
Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCMKaren Sliwa, Alexandre Mebazaa, Denise Hilfiker-Kleiner, et al.
ESC Heart Failure|May 8, 2024
Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and designJaclyn Carberry, Mark C Petrie, Matthew M Y Lee, et al.
European Journal of Heart Failure|June 19, 2024
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial DiseasesPetar M Seferović, Walter J Paulus, Giuseppe Rosano, et al.
European Journal of Heart Failure|September 15, 2023
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESCAntoni Bayes-Genis, Kieran F Docherty, Mark C Petrie, et al.
Heart (British Cardiac Society)|February 12, 2025
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trialShirley Sze, Iain Squire, Paul R Kalra, et al.
JAMA Cardiology|January 24, 2024
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER TrialOrly Vardeny, Akshay S Desai, Pardeep S Jhund, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Pageof 56